Bristol-Myers Squibb Company
SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Abstract:

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NR.sup.xR.sup.x, C(O)OH, C(O)NH.sub.2, C.sub.1-6 alkyl substiuted with zero to 6 R.sup.1a, or P(O)R.sup.1cR.sup.1c, or (ii) L R.sup.1; and A, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Z.sup.1, Z.sup.2, R.sup.1, R.sup.1a, R.sup.1c, R.sup.2, R.sup.3a, R.sup.3b, R.sup.x, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. ##STR00001##